Drugmaker Amneal agrees to $270 million U.S. opioid settlement

Amneal Pharmaceuticals (AMRX.O said on Friday it had reached a deal valued at more than $270 million to resolve claims it helped fuel the deadly U.S. opioid epidemic, becoming the latest drug company to settle lawsuits over the addiction crisis brought by states and local governments.